Search Results
You are looking at 1 - 5 of 5 items for
- Author: H Carlsten x
- Refine by access: All content x
Search for other papers by MC Erlandsson in
Google Scholar
PubMed
Search for other papers by CA Jonsson in
Google Scholar
PubMed
Search for other papers by MK Lindberg in
Google Scholar
PubMed
Search for other papers by C Ohlsson in
Google Scholar
PubMed
Search for other papers by H Carlsten in
Google Scholar
PubMed
Raloxifene is a selective estrogen receptor modulator approved for the prevention of osteoporosis in postmenopausal women. It is selective by having estrogen-agonistic effects on bone, vessels and blood lipids while it is antagonistic on mammary and uterine tissue. Our aim was to study the agonistic and antagonistic properties of the raloxifene analogue LY117018 (LY) on uterus, bone, B lymphopoiesis and B cell function. Oophorectomized and sham-operated animals were treated with s.c. injections of equipotent anti-osteoporotic doses of 17beta-estradiol (E2) (0.1 mg/kg) or LY (3 mg/kg) or vehicle as controls. Effects on bone mineral density (BMD) were studied using peripheral quantitative computed tomography, uterine weight was examined, B lymphopoiesis was examined using flow cytometry and B cell function in bone marrow and spleen was studied by the use of an ELISPOT assay. E2 and LY had similar effects on BMD and bone marrow B lymphopoiesis, while LY had a clear antagonistic effect on endogenous estrogen in uterine tissue and no stimulating effect on the frequency of Ig-producing B cells in sham-operated animals. Our results are discussed in the context of estrogen receptor biology, relations between the immune system and bone metabolism and also with respect to the estrogen-mediated effects on rheumatic diseases.
Search for other papers by MK Lindberg in
Google Scholar
PubMed
Search for other papers by M Erlandsson in
Google Scholar
PubMed
Search for other papers by SL Alatalo in
Google Scholar
PubMed
Search for other papers by S Windahl in
Google Scholar
PubMed
Search for other papers by G Andersson in
Google Scholar
PubMed
Search for other papers by JM Halleen in
Google Scholar
PubMed
Search for other papers by H Carlsten in
Google Scholar
PubMed
Search for other papers by JA Gustafsson in
Google Scholar
PubMed
Search for other papers by C Ohlsson in
Google Scholar
PubMed
Estrogens are important for the male skeleton. Osteoprotegerin (OPG), receptor activator of NF-kappa B ligand (RANKL), interleukin-6 (IL-6), IL-1 and tumor necrosis factor alpha (TNFalpha) have been suggested to be involved in the skeletal effects of estrogen. We treated orchidectomized mice with estradiol for 2 weeks and observed a 143% increase in the trabecular bone mineral density of the distal metaphysis of femur that was associated with a decreased OPG/RANKL mRNA ratio in vertebral bone. A similar decreased OPG/RANKL ratio was also seen after estrogen treatment of ovariectomized female mice. The effect of estrogen receptor (ER) inactivation on the OPG/RANKL ratio was dissected by using intact male mice lacking ER alpha (ERKO), ER beta (BERKO) or both receptors (DERKO). The expression of OPG was increased in ERKO and DERKO but not in BERKO male mice, resulting in an increased OPG/RANKL ratio. Furthermore, serum levels of IL-6 and tartrate-resistant acid phosphatase 5b (TRAP 5b) were decreased in ERKO and DERKO, but not in BERKO male mice. These results demonstrate that ER alpha, but not ER beta, is involved in the regulation of the vertebral OPG/RANKL ratio, serum levels of IL-6 and TRAP 5b in male mice.
Search for other papers by K L Gustafsson in
Google Scholar
PubMed
Search for other papers by K H Nilsson in
Google Scholar
PubMed
Search for other papers by H H Farman in
Google Scholar
PubMed
Search for other papers by A Andersson in
Google Scholar
PubMed
Search for other papers by V Lionikaite in
Google Scholar
PubMed
Search for other papers by P Henning in
Google Scholar
PubMed
Search for other papers by J Wu in
Google Scholar
PubMed
Search for other papers by S H Windahl in
Google Scholar
PubMed
Search for other papers by U Islander in
Google Scholar
PubMed
Search for other papers by S Movérare-Skrtic in
Google Scholar
PubMed
Search for other papers by K Sjögren in
Google Scholar
PubMed
Search for other papers by H Carlsten in
Google Scholar
PubMed
Search for other papers by J-Å Gustafsson in
Google Scholar
PubMed
Search for other papers by C Ohlsson in
Google Scholar
PubMed
Search for other papers by M K Lagerquist in
Google Scholar
PubMed
Estrogen treatment has positive effects on the skeleton, and we have shown that estrogen receptor alpha (ERα) expression in cells of hematopoietic origin contributes to a normal estrogen treatment response in bone tissue. T lymphocytes are implicated in the estrogenic regulation of bone mass, but it is not known whether T lymphocytes are direct estrogen target cells. Therefore, the aim of this study was to determine the importance of ERα expression in T lymphocytes for the estrogenic regulation of the skeleton using female mice lacking ERα expression specifically in T lymphocytes (Lck-ERα−/−) and ERαflox/flox littermate (control) mice. Deletion of ERα expression in T lymphocytes did not affect bone mineral density (BMD) in sham-operated Lck-ERα−/− compared to control mice, and ovariectomy (ovx) resulted in a similar decrease in BMD in control and Lck-ERα−/− mice compared to sham-operated mice. Furthermore, estrogen treatment of ovx Lck-ERα−/− led to an increased BMD that was indistinguishable from the increase seen after estrogen treatment of ovx control mice. Detailed analysis of both the appendicular (femur) and axial (vertebrae) skeleton showed that both trabecular and cortical bone parameters responded to a similar extent regardless of the presence of ERα in T lymphocytes. In conclusion, ERα expression in T lymphocytes is dispensable for normal estrogenic regulation of bone mass in female mice.
Search for other papers by Annica Andersson in
Google Scholar
PubMed
Search for other papers by Anna E Törnqvist in
Google Scholar
PubMed
Search for other papers by Sofia Moverare-Skrtic in
Google Scholar
PubMed
Search for other papers by Angelina I Bernardi in
Google Scholar
PubMed
Search for other papers by Helen H Farman in
Google Scholar
PubMed
Search for other papers by Pierre Chambon in
Google Scholar
PubMed
Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Cecilia Engdahl in
Google Scholar
PubMed
Search for other papers by Marie K Lagerquist in
Google Scholar
PubMed
Search for other papers by Sara H Windahl in
Google Scholar
PubMed
Search for other papers by Hans Carlsten in
Google Scholar
PubMed
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Search for other papers by Ulrika Islander in
Google Scholar
PubMed
Apart from the role of sex steroids in reproduction, sex steroids are also important regulators of the immune system. 17β-estradiol (E2) represses T and B cell development, but augments B cell function, possibly explaining the different nature of immune responses in men and women. Both E2 and selective estrogen receptors modulators (SERM) act via estrogen receptors (ER). Activating functions (AF)-1 and 2 of the ER bind to coregulators and thus influence target gene transcription and subsequent cellular response to ER activation. The importance of ERαAF-1 and AF-2 in the immunomodulatory effects of E2/SERM has previously not been reported. Thus, detailed studies of T and B lymphopoiesis were performed in ovariectomized E2-, lasofoxifene- or raloxifene-treated mice lacking either AF-1 or AF-2 domains of ERα, and their wild-type littermate controls. Immune cell phenotypes were analyzed with flow cytometry. All E2 and SERM-mediated inhibitory effects on thymus cellularity and thymic T cell development were clearly dependent on both ERαAFs. Interestingly, divergent roles of ERαAF-1 and ERαAF-2 in E2 and SERM-mediated modulation of bone marrow B lymphopoiesis were found. In contrast to E2, effects of lasofoxifene on early B cells did not require functional ERαAF-2, while ERαAF-1 was indispensable. Raloxifene reduced early B cells partly independent of both ERαAF-1 and ERαAF-2. Results from this study increase the understanding of the impact of ER modulation on the immune system, which can be useful in the clarification of the molecular actions of SERMs and in the development of new SERM.
Search for other papers by MK Lindberg in
Google Scholar
PubMed
Search for other papers by Z Weihua in
Google Scholar
PubMed
Search for other papers by N Andersson in
Google Scholar
PubMed
Search for other papers by S Moverare in
Google Scholar
PubMed
Search for other papers by H Gao in
Google Scholar
PubMed
Search for other papers by O Vidal in
Google Scholar
PubMed
Search for other papers by M Erlandsson in
Google Scholar
PubMed
Search for other papers by S Windahl in
Google Scholar
PubMed
Search for other papers by G Andersson in
Google Scholar
PubMed
Search for other papers by DB Lubahn in
Google Scholar
PubMed
Search for other papers by H Carlsten in
Google Scholar
PubMed
Search for other papers by K Dahlman-Wright in
Google Scholar
PubMed
Search for other papers by JA Gustafsson in
Google Scholar
PubMed
Search for other papers by C Ohlsson in
Google Scholar
PubMed
Estrogen exerts a variety of important physiological effects, which have been suggested to be mediated via the two known estrogen receptors (ERs), alpha and beta. Three-month-old ovariectomized mice, lacking one or both of the two estrogen receptors, were given estrogen subcutaneously (2.3 micro g/mouse per day) and the effects on different estrogen-responsive parameters, including skeletal effects, were studied. We found that estrogen increased the cortical bone dimensions in both wild-type (WT) and double ER knockout (DERKO) mice. DNA microarray analysis was performed to characterize this effect on cortical bone and it identified four genes that were regulated by estrogen in both WT and DERKO mice. The effect of estrogen on cortical bone in DERKO mice might either be due to remaining ERalpha activity or represent an ERalpha/ERbeta-independent effect. Other effects of estrogen, such as increased trabecular bone mineral density, thymic atrophy, fat reduction and increased uterine weight, were mainly ERalpha mediated.
